[Skip to Navigation]
Comment & Response
August 2017

Outcomes Associated With Subcutaneous Implantable Cardioverter Defibrillators—Reply

Author Affiliations
  • 1Division of Cardiology, Duke University Hospital, Durham, North Carolina
  • 2Duke Clinical Research Institute, Durham, North Carolina
JAMA Cardiol. 2017;2(8):925-926. doi:10.1001/jamacardio.2017.0304

In Reply We thank Wase et al for their interest in our article1 and comments regarding chronic kidney disease and the use of defibrillation threshold (DFT) testing among subcutaneous implantable cardioverter defibrillator (S-ICD) recipients. Wase et al raised concerns about our finding of underuse of DFT testing among all patients with S-ICDs and emphasized that the class I recommendation for DFT testing after S-ICD implantation should be strictly followed, citing increased DFTs2,3 and arrhythmic death3 among patients with chronic kidney disease receiving transvenous ICDs.

Add or change institution